Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corporation on October 21, 2024, covering events occurring on October 16, 2024. The Company is a Delaware corporation with its principal executive offices in Burlington, MA, and its common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statement data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- Appointment: Phillip Meikle was appointed to the Board of Directors on October 16, 2024.
- Compensation: Mr. Meikle will be compensated in the same manner as the Company's other directors.
- Background: Mr. Meikle is a seasoned healthcare executive with over 32 years of orthopedic and spine industry experience. He founded Biosystems of New England, Inc. in 1992, serving as CEO and President until selling the company to Stryker in 2019. He has served as a Stryker consultant for the past five years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The Company confirmed that Mr. Meikle was not selected under any arrangement requiring disclosure under Item 404(a) of Regulation S-K and is not aware of any transactions with him requiring such disclosure.
Investor Verification Checklist
- Verify the official press release dated October 21, 2024, for additional details on the Board appointment.
- Review the Company's most recent 10-Q or 10-K filing for current financial metrics, as this 8-K contains no financial data.
- Confirm the total number of directors on the Board following this appointment to assess Board composition.
- Check for any subsequent filings regarding Mr. Meikle's specific compensation package or equity grants.